Inovio Pharmaceuticals Company Profile (NASDAQ:INO)

About Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals logoInovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:INO
  • CUSIP: N/A
  • Web: www.inovio.com
Capitalization:
  • Market Cap: $554.9 million
  • Outstanding Shares: 90,227,000
Average Prices:
  • 50 Day Moving Avg: $5.73
  • 200 Day Moving Avg: $6.65
  • 52 Week Range: $5.28 - $9.86
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.26
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $51.84 million
  • Price / Sales: 10.70
  • Book Value: $1.59 per share
  • Price / Book: 3.87
Profitability:
  • EBIDTA: ($70,600,000.00)
  • Net Margins: -153.46%
  • Return on Equity: -63.67%
  • Return on Assets: -46.77%
Debt:
  • Current Ratio: 3.90%
  • Quick Ratio: 3.90%
Misc:
  • Average Volume: 1.52 million shs.
  • Beta: 2.75
  • Short Ratio: 4.01
 

Frequently Asked Questions for Inovio Pharmaceuticals (NASDAQ:INO)

What is Inovio Pharmaceuticals' stock symbol?

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?

Shares of Inovio Pharmaceuticals reverse split on the morning of Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced its earnings results on Tuesday, August, 8th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.08. The firm had revenue of $20.41 million for the quarter, compared to analyst estimates of $16.29 million. Inovio Pharmaceuticals had a negative net margin of 153.46% and a negative return on equity of 63.67%. The firm's revenue for the quarter was up 229.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.26) earnings per share. View Inovio Pharmaceuticals' Earnings History.

Where is Inovio Pharmaceuticals' stock going? Where will Inovio Pharmaceuticals' stock price be in 2017?

10 analysts have issued 12-month price objectives for Inovio Pharmaceuticals' stock. Their predictions range from $10.00 to $40.00. On average, they anticipate Inovio Pharmaceuticals' stock price to reach $20.90 in the next twelve months. View Analyst Ratings for Inovio Pharmaceuticals.

What are analysts saying about Inovio Pharmaceuticals stock?

Here are some recent quotes from research analysts about Inovio Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Inovio is a development-stage biopharmaceutical company is focused on the development of treatments targeting various forms of cancer and infectious diseases. We are pleased with the company’s collaborations with other firms for pipeline development. Shares of Inovio have outperformed the Medical-Biomedical/Genetics industry so far this year. However, Inovio suffered a setback with the FDA placing clinical hold on the proposed phase III program on its lead pipeline candidate, VGX-3100 in Oct 2016. Though in Apr 2017, Inovio submitted a complete response to the FDA for the initiation of the study, FDA decision is still pending. Estimates have been going up lately ahead of the company’s Q2 earnings release. The company has negative record of earnings surprises in recent quarters." (7/11/2017)
  • 2. Maxim Group analysts commented, "Inovio announced a collaboration with Roche (RHHBY – $34.10 – NR) to evaluate their DNA-based immunotherapies INO-5401 (multiple cancer antigens) and INO-9012 (IL-12 immune stimulator) with Tecentriq (PD-L1 checkpoint) in advanced bladder cancer." (6/1/2017)

Who are some of Inovio Pharmaceuticals' key competitors?

Who are Inovio Pharmaceuticals' key executives?

Inovio Pharmaceuticals' management team includes the folowing people:

  • Jong Joseph Kim Ph.D., President, Chief Executive Officer, Director
  • Peter D. Kies, Chief Financial Officer
  • Niranjan Y. Sardesai Ph.D., Chief Operating Officer
  • Mark L. Bagarazzi M.D., Chief Medical Officer
  • Avtar S. Dhillon M.D., Non-Executive Chairman of the Board
  • George W. Bickerstaff III, Director
  • David B. Weiner, Director
  • Simon X. Benito, Independent Director
  • Angel Cabrera Ph.D., Independent Director

Who owns Inovio Pharmaceuticals stock?

Inovio Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.32%), Wasatch Advisors Inc. (2.89%), State Street Corp (2.40%), Northern Trust Corp (1.20%), Schwab Charles Investment Management Inc. (0.45%) and Bank of New York Mellon Corp (0.44%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jong Joseph Kim, Morton Collins, Niranjan Sardesai and Simon X Benito. View Institutional Ownership Trends for Inovio Pharmaceuticals.

Who sold Inovio Pharmaceuticals stock? Who is selling Inovio Pharmaceuticals stock?

Inovio Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Stoneridge Investment Partners LLC, New York State Common Retirement Fund, ING Groep NV, TIAA CREF Investment Management LLC, Wells Fargo & Company MN, Russell Investments Group Ltd. and Teachers Advisors LLC. Company insiders that have sold Inovio Pharmaceuticals stock in the last year include David B Weiner and Jong Joseph Kim. View Insider Buying and Selling for Inovio Pharmaceuticals.

Who bought Inovio Pharmaceuticals stock? Who is buying Inovio Pharmaceuticals stock?

Inovio Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Candriam Luxembourg S.C.A., GSA Capital Partners LLP, Vanguard Group Inc., Virtu KCG Holdings LLC, State of Wisconsin Investment Board, Public Employees Retirement System of Ohio and Private Capital Advisors Inc.. Company insiders that have bought Inovio Pharmaceuticals stock in the last two years include Morton Collins and Niranjan Sardesai. View Insider Buying and Selling for Inovio Pharmaceuticals.

How do I buy Inovio Pharmaceuticals stock?

Shares of Inovio Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Inovio Pharmaceuticals' stock price today?

One share of Inovio Pharmaceuticals stock can currently be purchased for approximately $6.15.


MarketBeat Community Rating for Inovio Pharmaceuticals (NASDAQ INO)
Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  297 (Vote Outperform)
Underperform Votes:  141 (Vote Underperform)
Total Votes:  438
MarketBeat's community ratings are surveys of what our community members think about Inovio Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Inovio Pharmaceuticals (NASDAQ:INO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 8 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $20.90 (239.84% upside)

Analysts' Ratings History for Inovio Pharmaceuticals (NASDAQ:INO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/22/2017HC WainwrightReiterated RatingBuy$13.00LowView Rating Details
9/12/2017Maxim GroupReiterated RatingBuy$12.00LowView Rating Details
9/6/2017Citigroup Inc.Initiated CoverageBuy -> Buy$10.00HighView Rating Details
7/18/2017AegisReiterated RatingBuy$14.00LowView Rating Details
6/8/2017Piper Jaffray CompaniesUpgradeNeutral -> Overweight$14.00MediumView Rating Details
5/25/2017Stifel NicolausReiterated RatingBuy$11.00HighView Rating Details
5/1/2017NomuraReiterated RatingBuy$40.00LowView Rating Details
5/1/2017Jefferies Group LLCReiterated RatingNeutral$38.00LowView Rating Details
5/1/2017BNP ParibasReiterated RatingNeutral$39.00LowView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$18.00N/AView Rating Details
6/21/2016Rodman & RenshawReiterated RatingBuy$17.00N/AView Rating Details
(Data available from 9/24/2015 forward)

Earnings

Earnings History for Inovio Pharmaceuticals (NASDAQ:INO)
Earnings by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)
Earnings History by Quarter for Inovio Pharmaceuticals (NASDAQ INO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 17($0.21)($0.13)$16.29 million$20.41 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.31)($0.31)$5.83 million$10.40 millionViewN/AView Earnings Details
3/15/2017Q4 2016($0.29)($0.35)$5.21 million$8.50 millionViewN/AView Earnings Details
11/9/2016Q316($0.26)($0.28)$5.16 million$12.54 millionViewListenView Earnings Details
8/8/2016Q2($0.21)($0.26)$4.95 million$6.20 millionViewN/AView Earnings Details
5/9/2016Q1($0.14)($0.11)$4.75 million$8.10 millionViewN/AView Earnings Details
3/14/2016Q4($0.20)($0.25)$6.96 million$5.94 millionViewListenView Earnings Details
11/9/2015Q3$0.04$0.07$1.84 million$24.18 millionViewN/AView Earnings Details
8/10/2015Q215($0.13)($0.10)$5.52 million$5.30 millionViewListenView Earnings Details
5/11/2015Q1($0.11)($0.18)$7.04 million$5.20 millionViewListenView Earnings Details
3/16/2015Q414($0.10)($0.12)$5.24 million$2.50 millionViewN/AView Earnings Details
11/10/2014Q314($0.11)($0.12)$5.60 million$1.80 millionViewN/AView Earnings Details
8/11/2014Q214($0.17)($0.19)$1.80 million$3.80 millionViewN/AView Earnings Details
5/12/2014Q114($0.04)($0.05)$1.41 million$2.40 millionViewN/AView Earnings Details
3/17/2014Q413($0.03)($0.04)$1.36 million$1.70 millionViewN/AView Earnings Details
11/11/2013Q3($0.02)($0.16)$2.99 million$9.50 millionViewListenView Earnings Details
11/7/2012Q312($0.05)($0.05)$2.07 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Inovio Pharmaceuticals (NASDAQ:INO)
Current Year EPS Consensus Estimate: $-0.92 EPS
Next Year EPS Consensus Estimate: $-1.17 EPS

Dividends

Dividend History for Inovio Pharmaceuticals (NASDAQ:INO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Inovio Pharmaceuticals (NASDAQ:INO)
Insider Ownership Percentage: 10.60%
Institutional Ownership Percentage: 24.83%
Insider Trades by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)
Institutional Ownership by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)
Insider Trades by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/25/2017David B WeinerDirectorSell8,000$8.00$64,000.00View SEC Filing  
3/31/2017Jong Joseph KimCEOSell147,180$6.54$962,557.20View SEC Filing  
3/27/2017Morton CollinsDirectorBuy21,300$6.25$133,125.00View SEC Filing  
8/29/2016Niranjan SardesaiCOOSell21,800$9.30$202,740.00View SEC Filing  
6/28/2016Morton CollinsDirectorBuy10,000$9.13$91,300.00View SEC Filing  
5/18/2016Simon X BenitoDirectorSell6,250$10.37$64,812.50View SEC Filing  
4/15/2016Morton CollinsDirectorBuy68,400$9.52$651,168.00View SEC Filing  
9/30/2015Niranjan SardesaiCOOBuy4,000$5.50$22,000.00View SEC Filing  
8/14/2015Simon X BenitoDirectorBuy6,000$7.21$43,260.00View SEC Filing  
4/13/2015Angel CabreraDirectorBuy8,000$9.53$76,240.00View SEC Filing  
10/9/2014Peter KiesCFOBuy3,960$10.10$39,996.00View SEC Filing  
8/21/2014Morton CollinsDirectorBuy8,000$10.01$80,080.00View SEC Filing  
8/20/2014Morton CollinsDirectorBuy40,600$9.74$395,444.00View SEC Filing  
8/12/2014Jong Joseph KimCEOBuy250,000$9.06$2,265,000.00View SEC Filing  
8/12/2014Niranjan SardesaiCOOBuy2,550$8.70$22,185.00View SEC Filing  
4/15/2014Jong Joseph KimCEOBuy25,000$2.25$56,250.00View SEC Filing  
11/13/2013Morton CollinsDirectorBuy254,500$1.82$463,190.00View SEC Filing  
4/16/2013Mark BagarazziInsiderBuy60,000$0.56$33,600.00View SEC Filing  
4/2/2013Jong Joseph KimCEOBuy90,000$0.50$45,000.00View SEC Filing  
3/22/2013Angel CabreraDirectorBuy40,000$0.54$21,600.00View SEC Filing  
3/20/2013Jong Joseph KimCEOBuy60,000$0.53$31,800.00View SEC Filing  
3/20/2013Niranjan SardesaiCOOBuy25,000$0.53$13,250.00View SEC Filing  
1/15/2013Morton CollinsDirectorBuy100,000$0.67$67,000.00View SEC Filing  
11/14/2012Austin W & Greenhouse Da MarxeMajor ShareholderSell622,550$0.53$329,951.50View SEC Filing  
8/15/2012Angel CabreraDirectorBuy75,000$0.59$44,250.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Inovio Pharmaceuticals (NASDAQ:INO)
Latest Headlines for Inovio Pharmaceuticals (NASDAQ:INO)
Source:
DateHeadline
americanbankingnews.com logoInovio Pharmaceuticals, Inc. (INO) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - September 23 at 8:50 PM
americanbankingnews.com logoInovio Pharmaceuticals, Inc. (INO) Expected to Post Earnings of -$0.22 Per Share
www.americanbankingnews.com - September 23 at 2:26 PM
americanbankingnews.com logoInovio Pharmaceuticals' (INO) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - September 22 at 5:44 PM
nasdaq.com logoETF Preview: ETFs, Futures Mixed Following Weekly Jobless Claims, Philly Fed Manufacturing Data
www.nasdaq.com - September 21 at 4:07 PM
globenewswire.com logoInovio dMAb™ Constructs Shrink Prostate Tumors and Protect Against Lethal Antibiotic-Resistant Bacterial Infection ... - GlobeNewswire (press release)
www.globenewswire.com - September 21 at 9:29 AM
finance.yahoo.com logoInovio dMAb™ Constructs Shrink Prostate Tumors and Protect Against Lethal Antibiotic-Resistant Bacterial Infection In Preclinical Studies
finance.yahoo.com - September 21 at 9:29 AM
finance.yahoo.com logoInovio shares jump 5% premarket after two peer-reviewed paper support its research
finance.yahoo.com - September 21 at 9:29 AM
streetinsider.com logoInovio Pharma (INO) and Its Partners Begin Phase 1/2a Trial to ... - StreetInsider.com
www.streetinsider.com - September 20 at 4:21 PM
finance.yahoo.com logoInovio Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : INO-US : September 20, 2017
finance.yahoo.com - September 20 at 4:21 PM
reuters.com logoBRIEF-Inovio and partners initiate Phase 1/2A clinical trial to further advance its vaccine against deadly MERS infection
www.reuters.com - September 18 at 7:23 PM
finance.yahoo.com logoInovio and Partners Initiate Phase 1/2a Clinical Trial To Further Advance Its Vaccine Against Deadly MERS Infection
finance.yahoo.com - September 18 at 7:23 PM
americanbankingnews.com logoInovio Pharmaceuticals, Inc. (INO) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - September 17 at 10:58 PM
americanbankingnews.com logoInovio Pharmaceuticals, Inc. (INO) Stock Rating Reaffirmed by Maxim Group
www.americanbankingnews.com - September 17 at 10:58 PM
seekingalpha.com logoInovio Pharmaceuticals (INO) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 3:13 AM
globenewswire.com logoINO-5150 generated antigen specific T cell immune responses in a phase 1b clinical study
globenewswire.com - September 11 at 8:38 PM
rttnews.com logoInovio Pharma Reports Promising Phase 1b Clinical Trial Data Of INO-5150
www.rttnews.com - September 11 at 8:38 PM
finance.yahoo.com logoInovio’s Cancer Immunotherapy (INO-5150) Slowed PSA Rise and Significantly Increased PSA Doubling Times In Patients with Recurrent Prostate Cancer
finance.yahoo.com - September 11 at 8:38 PM
americanbankingnews.com logoInovio Pharmaceuticals, Inc. (INO) Earns Buy Rating from Analysts at Citigroup Inc.
www.americanbankingnews.com - September 10 at 8:16 PM
americanbankingnews.com logoInovio Pharmaceuticals, Inc. (INO) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - September 9 at 4:16 PM
finance.yahoo.com logoSurging Earnings Estimates Signal Good News for Inovio (INO)
finance.yahoo.com - September 7 at 8:11 PM
finance.yahoo.com logoIs Inovio Pharmaceuticals Stock Poised for a Rebound?
finance.yahoo.com - September 6 at 6:25 AM
americanbankingnews.com logo$14.04 Million in Sales Expected for Inovio Pharmaceuticals, Inc. (INO) This Quarter
www.americanbankingnews.com - September 6 at 3:16 AM
fool.com logoIs Inovio Pharmaceuticals Stock Poised for a Rebound? - Motley Fool
www.fool.com - August 30 at 2:17 AM
americanbankingnews.com logoInovio Pharmaceuticals, Inc. (INO) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - August 29 at 9:14 PM
americanbankingnews.com logoFinancial Review: Inovio Pharmaceuticals (INO) and Abeona Therapeutics (ABEO)
www.americanbankingnews.com - August 24 at 10:26 PM
finance.yahoo.com logoInovio Pharmaceuticals to Participate in Upcoming Investment Conferences
finance.yahoo.com - August 24 at 7:59 AM
thestreet.com logoIronwood Shares Jump on FDA Approval for Hyperuricemia Drug - Biotech Movers - TheStreet.com
www.thestreet.com - August 22 at 12:07 AM
americanbankingnews.com logoInovio Pharmaceuticals, Inc. (INO) Expected to Post Quarterly Sales of $14.04 Million
www.americanbankingnews.com - August 19 at 1:34 PM
americanbankingnews.com logo-$0.22 EPS Expected for Inovio Pharmaceuticals, Inc. (INO) This Quarter
www.americanbankingnews.com - August 17 at 8:18 AM
americanbankingnews.com logoInovio Pharmaceuticals, Inc. (INO) Short Interest Update
www.americanbankingnews.com - August 12 at 1:44 AM
finance.yahoo.com logoInovio (INO) Q2 Loss Narrower Than Expected, Revenues Beat
finance.yahoo.com - August 11 at 11:24 PM
americanbankingnews.com logoInovio Pharmaceuticals, Inc. (NASDAQ:INO) Posts Earnings Results
www.americanbankingnews.com - August 10 at 4:04 PM
nasdaq.com logoInovio (INO) Q2 Loss Narrower Than Expected, Revenues Beat - Nasdaq
www.nasdaq.com - August 9 at 8:09 PM
finance.yahoo.com logoEdited Transcript of INO earnings conference call or presentation 8-Aug-17 8:30pm GMT
finance.yahoo.com - August 9 at 5:40 AM
finance.yahoo.com logoInovio reports 2Q loss
finance.yahoo.com - August 9 at 5:40 AM
rttnews.com logoEARNINGS SUMMARY: Details of Inovio Pharmaceuticals Inc. Q2 Earnings Report
www.rttnews.com - August 9 at 12:37 AM
nasdaq.com logoInovio Pharmaceuticals Reports 2017 Second Quarter Financial Results - Nasdaq
www.nasdaq.com - August 8 at 7:34 PM
finance.yahoo.com logoHere's Why Inovio Pharmaceuticals, Inc. Sank 30.8% in July
finance.yahoo.com - August 8 at 7:34 PM
finance.yahoo.com logoInovio Pharmaceuticals Reports 2017 Second Quarter Financial Results
finance.yahoo.com - August 8 at 7:34 PM
fool.com logoHere's Why Inovio Pharmaceuticals, Inc. Sank 30.8% in July
www.fool.com - August 8 at 1:32 PM
seekingalpha.com logoInovio: The Dilution Solution - Seeking Alpha
seekingalpha.com - August 8 at 5:26 AM
americanbankingnews.com logoInovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - August 4 at 8:44 PM
finance.yahoo.com logoReport Coverage on Real Estate Stocks Inovalis REIT InterRent REIT BTB REIT and Dream Industrial REIT
finance.yahoo.com - August 4 at 8:09 PM
finance.yahoo.com logoInovio Pharmaceuticals, Inc. – Value Analysis (NASDAQ:INO) : August 4, 2017
finance.yahoo.com - August 4 at 1:08 AM
finance.yahoo.com logoAnalysts’ Recommendations for Regeneron in July 2017
finance.yahoo.com - August 1 at 3:29 PM
americanbankingnews.com logo$18.75 Million in Sales Expected for Inovio Pharmaceuticals, Inc. (INO) This Quarter
www.americanbankingnews.com - August 1 at 8:53 AM
americanbankingnews.com logo Analysts Expect Inovio Pharmaceuticals, Inc. (INO) to Announce -$0.18 EPS
www.americanbankingnews.com - July 30 at 7:42 AM
americanbankingnews.com logoInovio Pharmaceuticals, Inc. (INO) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - July 29 at 3:35 PM
prnewswire.com logoHow These Biotech Stocks are Performing? -- Inovio Pharma, Intra Cellular Therapies, OncoMed Pharma, and ... - PR Newswire (press release)
www.prnewswire.com - July 28 at 11:20 PM
nasdaq.com logoInovio Pharmaceuticals to Report Second Quarter 2017 Financial ... - Nasdaq
www.nasdaq.com - July 28 at 3:47 AM

Social

Chart

Inovio Pharmaceuticals (INO) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by MarketBeat.com Staff